Physician profile
Nancy Hunter
NPI 1538539143
$4,439.44
in general payments reported to CMS, 2019-2025
32 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $490 · 2023: $1,045 · 2024: $1,293 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $695.99 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $623.14 | 2021-2025 | |
| Exact Sciences Corporation | $442.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $366.53 | 2021-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $365.81 | 2021-2025 | |
| Lilly USA, LLC | $321.21 | 2021-2025 | Mounjaro, Trulicity, Emgality |
| Novo Nordisk INC | $288.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $241.77 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $152.85 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lundbeck LLC | $100.63 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.25 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $87.79 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.63 | 2023-2024 | Caplyta |
| Insulet Corporation | $70.10 | 2024-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $63.08 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $61.96 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.84 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $38.59 | 2023-2024 | Eliquis |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.74 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $30.55 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $28.03 | 2023 | Imcivree |
| Abbott Laboratories | $24.70 | 2021 | |
| Acadia Pharmaceuticals INC | $23.98 | 2024 | Daybue |
| Phathom Pharmaceuticals, INC. | $23.11 | 2025 | Voquezna |
| Gilead Sciences, INC. | $22.49 | 2023 | |
| Eisai INC. | $22.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.55 | 2021 | |
| Alkermes, INC. | $19.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.58 | 2025 | Spravato |
| Hologic Sales and Service, LLC | $14.45 | 2022 | |
| Dexcom, INC. | $13.47 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.